ANTIBODY treatment with NG101 significantly improves motor function and functional independence in patients with incomplete spinal cord injuries, recent research has shown, but no benefit in complete injuries.
A multi-centre clinical trial conducted at 13 hospitals in Germany, Switzerland, the Czech Republic, and Spain evaluated the efficacy of the NG101 antibody in acute cervical spinal cord injury rehabilitation. The antibody neutralises Nogo-A, a protein that inhibits nerve regeneration, potentially promoting neural repair. The trial included 126 participants aged 18–70 with tetraplegia (spinal injuries affecting arm and hand functions). Participants received either the antibody or a placebo over six injections within a comprehensive care programme.
This randomised, double-blind, placebo-controlled trial assessed motor recovery using the Upper Extremity Motor Score (UEMS). Incomplete spinal cord injury patients treated with NG101 showed significant improvement in voluntary hand and arm muscle activation and functional independence compared to placebo. However, no significant improvements were observed in patients with complete injuries. Adverse events were consistent across both groups, with no antibody-related side effects reported.
The findings highlight NG101’s potential to transform rehabilitation strategies for incomplete spinal cord injuries. A follow-up study starting December 2024 aims to confirm these results, refining patient selection to identify those most likely to benefit. If further trials affirm safety and efficacy, NG101 may play a crucial role in clinical management, offering hope to individuals facing significant disability.
Katrina Thornber, EMJ
Reference
Weidner N. Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial. The Lancet Neurology. 2025;24(1):42-53.
